Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex.
Yuan L, Ji W, Dwyer BG, Lu J, Bian J, Colombo GM, Martinez MJ, Fernandez D, Phillips NA, Tang MT, Zhou CW, Quispe Calla NE, Guzman Huancas C, Eckart M, Tran J, Jones HM, Qiu T, Doench JG, Rees MG, Roth JA, Cameron MD, Charville GW, Kuo CJ, Dixon SJ, Zhang T, Hinshaw SM, Gray NS, Corsello SM. Cancer Discov. 2025 Dec 2;15(12):2505-2529. doi: 10.1158/2159-8290.CD-25-0271. PMID: 40891634; PMCID: PMC12670082. [PubMed]